Better medicine is in our(synthetic) DNA

Better medicine is in our(synthetic) DNA

A path to better medicines

With our novel DNA base pair, we are designing and building protein therapeutics to create an entirely new generation of tailored medicines to improve how we treat disease.

DNA research: the path to Synthorins™


Mendel publishes on the heredity of peas and establishes the first laws of genetics.


Avery, McLeod, McCarty define DNA as the carrier of genetic information.


Chargaff establishes rules of base pairing.


Wilkins, Franklin, Watson, and Crick publish the double helix structure of DNA.


Hoagland and Zamecnik discover tRNA.


Rich publishes the first proposal of unnatural base pairs (UBP) and selective pairing of DisoC and DisoG via H-bonding patterns


Nirenberg, Leder, Khorana, and Holley describe triplet nature of the genetic code and genetic code translation.


Cohen and Boyer discover recombinant DNA technology.


Mullis invents the polymerase chain reaction (PCR) technique.


Benner demonstrates in vitro replication and transcription of isoC and isoG.


Benner publishes first in vitro translation using isoC–isoG pair and isoCAG codon.


Kool demonstrates selective dA-dF pairing with reduced complementary H-bonding.


Two scientific teams publish the first human genome sequences.


Hirao publishes first UBP pair that could be PCR amplified with an error rate below 1%.


Romesberg lab publishes first UBP pairs, d5SICS-dNaM (X) and d5SICS-dMMO2 (Y), that can be efficiently PCR amplified and transcribed.


Romesberg lab shows nucleotide transporter allows for replication of XY genetic information in E. coli.


Synthorx founded with technology licensed from the Romesberg Lab at The Scripps Research Institute and secures $6.25M Series A.


Demonstration of in vitro translation of UBPs (X and Y): Synthorx identifies codons and validates in vitro translation.


Synthorx completes $10M Series B and initiates in vivo platform and internal pipeline.


Synthorx initiates scalable recombinant protein production (synthorins) and begins lead candidate selection in two programs.


Romesberg lab publishes on a semi-synthetic organism that stores and retrieves increased genetic information.


Synthorx starts two IND-enabling programs.


Synthorx completes $63M Series C financing.


Synthorx raises $150.7 million in initial public offering. $THOR trading begins.


Synthorx opens HAMMER, a global, Phase 1/2, first-in-human clinical trial of THOR-707, with Australia being the first region to enroll patients. The company receives clearance from FDA for the IND Application for THOR-707, paving the way for enrollment to proceed in the US.

Protein therapeutics have delivered tremendous value to patients, but have many limitations that cannot be corrected utilizing the 20 natural amino acids. With Synthorx’s Expanded Genetic Alphabet platform technology, we can design and scale-up novel proteins with improved pharmacological properties, with the goal of making more efficacious, safer, and convenient therapeutics for patients. 

The Synthorx team

At Synthorx, we focus on making significant advancements in protein design to deliver optimized therapeutics – called Synthorins – to improve the lives of people with cancer and autoimmune disorders. While we are a diverse group of people as employees of Synthorx, together, we are one for patients.

Title Address Description
Synthorx, Inc
11099 N Torrey Pines Rd, La Jolla, CA 92037, USA
11099 North Torrey Pines Road, Suite 290
La Jolla, CA 92037